Efficacy/effectiveness Safety Newborn (0-1 years) Children (2-9 years) Adolescents (10-18 years) Mumps Measles Rubella Varicella
Administration Efficacy/effectiveness Safety Newborn (0-1 years) Hepatitis B Diphtheria Pertussis Tetanus Haemophilus influenzae type B Poliomyelitis
immunodeficiency Agenda & Minutes Germany Measles Mumps Rubella Pertussis Varicella
Download:
Agenda & Minutes Germany Influenza Pertussis Measles Mumps Rubella Japanese encephalitis Varicella
Download:
NITAG recommendation Recommendation Chile Varicella
Download:
Recommendation Chile Haemophilus influenzae type B
Download:
Efficacy/effectiveness Safety Administration All age groups Haemophilus influenzae type B
Economic aspects Newborn (0-1 years) Children (2-9 years) Haemophilus influenzae type B
Efficacy/effectiveness Safety Adults (18+) Elderly (65+) Haemophilus influenzae type B
Recommendation Belgium Varicella
Download: